Figure 4.

Kaplan-Meier curves of progression-free survival in patients treated with palbociclib plus fulvestrant. (A): Patients treated for more than 3 cycles who had maximum grade ≥3 (n = 186) vs. maximum grade ≤2 neutropenia (n = 93), per investigator assessment. (B): Patients who had at least 1 dose reduction because of neutropenia (n = 100) versus no dose reduction (n = 245). (C): Patients who had no dose reduction but had a dose interruption or cycle delay due to neutropenia (n = 199) versus the remaining patients (n = 146). “Neutropenia” was any event having a preferred term equal to “neutropenia” or “neutrophil decreased.”

Abbreviations: CI, confidence interval; HR, hazard ratio; max, maximum; NE, not estimable; PFS, progression-free survival.